# Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

> **NCT06860958** · PHASE3 · RECRUITING · sponsor: **Tanta University** · enrollment: 60 (estimated)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Fluoxetine
- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06860958
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2027-03-20
- **Final completion:** 2027-08-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860958, "Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06860958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*